The U.S. Food and Drug Administration (FDA) has removed the partial hold on the clinical development of nomlabofusp, an…
Articles by Andrea Lobo
The U.S. Food and Drug Administration (FDA) has put Lexeo Therapeutics’ LX2006, a gene therapy candidate for heart disease…
The Committee for Medicinal Products for Human Use (CHMP) — an arm of the European Medicines Agency — is recommending…
A first group of patients has been treated with LX2006, an investigational gene therapy for heart disease in…
Short-read genome sequencing (SR-GS), a test that can identify difficult-to-detect mutations, may help to correctly diagnose atypical Friedreich’s ataxia…